Corporate presentation
Logotype for Immunovant Inc

Immunovant (IMVT) Corporate presentation summary

Event summary combining transcript, slides, and related documents.

Logotype for Immunovant Inc

Corporate presentation summary

9 Nov, 2026

Strategic focus and platform

  • Anti-FcRn strategy targets autoantibody-driven diseases; the class had >$4.3B in global sales in 2025 and 20+ indications announced or in development.

  • IMVT-1402 is positioned for potential best-in-class IgG reduction, with deep, rapid, dose-dependent reductions and a simple autoinjector; efficacy and safety claims remain subject to clinical evaluation.

  • Current trials are expected to potentially address ~500K US patients across Graves’ disease, ACPA+ difficult-to-treat RA, MG and CIDP.

  • All current IMVT-1402 trials use the intended commercial YpsoMate autoinjector; at-home or HCP administration takes <10 seconds.

Clinical development and milestones

  • Potentially registrational trials are enrolling in Graves’ disease, MG and CIDP; the regulatory status depends on future FDA alignment on trial design, endpoints, statistical plans and development strategy.

  • Topline data are targeted for 2027 in Graves’ disease and MG, and 2028 in CIDP; ACPA+ D2T RA had positive Period 2 data.

  • In Graves’ disease, batoclimab responders included 17 of 21 assessed patients who remained responders six months off treatment; 8 of 17 responders were off all medication at Week 48.

  • In MG, Phase 3 batoclimab data showed a 5.6-point MG-ADL reduction with 680 mg and 42% minimal symptom expression; comparisons were cross-trial, not head-to-head.

  • In CIDP, batoclimab Phase 2b data showed an 84% alNCAT response rate among patients with ≥70% IgG reduction; results informed IMVT-1402 trial design.

Difficult-to-treat RA results

  • IMVT-1402 600 mg met the Period 2 primary endpoint: Week 28 ACR20 response was 92.5% with continued 600 mg versus 75.6% after switching to placebo (p=0.0139).

  • Week 28 ACR50 responses were 80.0% with continued 600 mg versus 56.1% with placebo (nominal p=0.0117); ACR70 responses were 52.5% versus 36.6% (nominal p=0.1674).

  • Period 2 treatment-emergent adverse events occurred in 22.5% of 600 mg recipients versus 30.8% with placebo; no Grade ≥3 events, serious events or discontinuations due to adverse events were reported in these arms.

  • FDA interaction was planned for later in 2026 to determine the path forward for the D2T RA program.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Immunovant